Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

NCT03309111

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Mayo Clinic Cancer Center (MCCC) - Rochester Rochester, Minnesota, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View all 20 locations
View Trial Details
Completed

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

NCT03424603

Conditions
B Cells--Tumors, B-cell Lymphoma, Blood Protein Disorders, +26 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Arizona Oncology Associates, PC--HOPE Division Tucson, Arizona, United States
  • City of Hope Medical Center Duarte, California, United States
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
View all 22 locations
View Trial Details
Completed

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT03234972

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Peking Union Medical College Hospital Beijing, China
  • Peking University First Hospital Beijing, China
  • Peking University People s Hospital Beijing, China
  • Peking University Third Hospital Beijing, China
View all 27 locations
View Trial Details
Completed

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03430011

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 0006 Birmingham, Alabama, United States
  • Local Institution - 0007 Duarte, California, United States
  • Local Institution - 0059 Los Angeles, California, United States
  • Local Institution - 0010 San Francisco, California, United States
View all 20 locations
View Trial Details

Related conditions